MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com

Posted by ABMN Staff on Mar 31st, 2025

Equities research analysts at StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “buy” rating on the stock.

MEI Pharma Trading Up 0.4 %

NASDAQ:MEIP opened at $2.35 on Monday. The business’s fifty day moving average price is $2.59 and its 200 day moving average price is $2.72. The firm has a market capitalization of $15.66 million, a price-to-earnings ratio of -0.41 and a beta of 0.76. MEI Pharma has a 1-year low of $2.26 and a 1-year high of $4.11.

MEI Pharma (NASDAQ:MEIP – Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.48) EPS for the quarter. Equities analysts forecast that MEI Pharma will post -5.1 earnings per share for the current year.

Institutional Investors Weigh In On MEI Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in MEI Pharma during the fourth quarter valued at approximately $26,000. Northern Trust Corp boosted its holdings in shares of MEI Pharma by 54.5% during the 4th quarter. Northern Trust Corp now owns 35,596 shares of the company’s stock worth $88,000 after buying an additional 12,561 shares during the period. Toronto Dominion Bank bought a new stake in shares of MEI Pharma during the 4th quarter worth $62,000. Finally, World Investment Advisors LLC acquired a new position in MEI Pharma in the 3rd quarter valued at $71,000. 52.38% of the stock is currently owned by institutional investors and hedge funds.

About MEI Pharma

(Get Free Report)

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.